Noha Abdelgawad, Sean Wasserman, Mahmoud Tareq Abdelwahab, Angharad Davis, Cari Stek, Lubbe Wiesner, John Black, Graeme Meintjes, Robert J Wilkinson, Paolo Denti
BACKGROUND: Linezolid is evaluated in novel treatment regimens for tuberculous meningitis (TBM). Linezolid pharmacokinetics have not been characterized in this population, particularly in cerebrospinal fluid (CSF) where exposures may be affected by changes in protein concentration. Linezolid co-administration with high-dose rifampicin, has also not been studied. We aimed to characterize linezolid plasma and CSF pharmacokinetics in adults with TBM. METHODS: In LASER-TBM pharmacokinetic-substudy, the intervention groups received high-dose rifampicin (35mg/kg) plus linezolid 1200mg/day for 28days, then reduced to 600mg/day...
September 22, 2023: Journal of Infectious Diseases